Boundless Cost Of Revenue vs Depreciation And Amortization Analysis
BOLD Stock | USD 2.59 0.07 2.78% |
Boundless Bio, financial indicator trend analysis is way more than just evaluating Boundless Bio, Common prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Boundless Bio, Common is a good investment. Please check the relationship between Boundless Bio, Cost Of Revenue and its Depreciation And Amortization accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Cost Of Revenue vs Depreciation And Amortization
Cost Of Revenue vs Depreciation And Amortization Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Boundless Bio, Common Cost Of Revenue account and Depreciation And Amortization. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Boundless Bio,'s Cost Of Revenue and Depreciation And Amortization is -0.26. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Depreciation And Amortization in the same time period over historical financial statements of Boundless Bio, Common, assuming nothing else is changed. The correlation between historical values of Boundless Bio,'s Cost Of Revenue and Depreciation And Amortization is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Boundless Bio, Common are associated (or correlated) with its Depreciation And Amortization. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation And Amortization has no effect on the direction of Cost Of Revenue i.e., Boundless Bio,'s Cost Of Revenue and Depreciation And Amortization go up and down completely randomly.
Correlation Coefficient | -0.26 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Cost Of Revenue
Cost of Revenue is found on Boundless Bio, Common income statement and represents the costs associated with goods and services Boundless Bio, provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Most indicators from Boundless Bio,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Boundless Bio, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, Boundless Bio,'s Enterprise Value Multiple is projected to drop slightly based on the last few years of reporting.
2010 | 2022 | 2023 | 2024 (projected) | Interest Income | 96K | 668K | 5.3M | 5.5M | Net Interest Income | 96K | 668K | 5.3M | 5.5M |
Boundless Bio, fundamental ratios Correlations
Click cells to compare fundamentals
Boundless Bio, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Boundless Bio, fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 178.7M | 472.6M | 113.7M | 76.8M | 129.9M | 148.5M | |
Short Long Term Debt Total | 7.2M | 7.1M | 377K | 5.2M | 2.2M | 3.3M | |
Other Current Liab | 3.7M | (2.0M) | 2.4M | 4.0M | 4.9M | 2.6M | |
Total Current Liabilities | 17.7M | 23.9M | 3.9M | 7.7M | 9.4M | 10.0M | |
Total Stockholder Equity | 156.6M | 442.8M | (38.2M) | (81.7M) | (127.1M) | (120.7M) | |
Property Plant And Equipment Net | 24.4M | 32.1M | 3.1M | 7.7M | 4.6M | 4.3M | |
Current Deferred Revenue | 5.6M | 7.7M | 2.2M | 3.9M | 3.5M | 3.6M | |
Net Debt | (31.8M) | (137.3M) | (33.9M) | (5.8M) | (21.5M) | (22.6M) | |
Retained Earnings | (190.6M) | (319.5M) | (40.8M) | (86.7M) | (136.1M) | (142.9M) | |
Accounts Payable | 3.9M | 8.1M | 1.1M | 1.4M | 2.2M | 2.5M | |
Cash | 39.0M | 144.3M | 34.3M | 11.0M | 23.7M | 38.5M | |
Non Current Assets Total | 41.7M | 52.8M | 39.1M | 8.8M | 5.7M | 5.4M | |
Non Currrent Assets Other | 3.1M | 6.4M | 1.1M | 533K | 555K | 527.3K | |
Cash And Short Term Investments | 133.6M | 414.3M | 73.0M | 66.7M | 120.8M | 121.8M | |
Short Term Investments | 94.6M | 270.0M | 38.7M | 55.8M | 97.0M | 83.3M | |
Liabilities And Stockholders Equity | 178.7M | 472.6M | 113.7M | 76.8M | 129.9M | 148.5M | |
Non Current Liabilities Total | 6.1M | 10.5M | 148.0M | 150.8M | 247.6M | 260.0M | |
Other Current Assets | 3.4M | 5.5M | 1.5M | 1.3M | 3.5M | 2.5M | |
Other Stockholder Equity | 47.3M | 462.3M | 2.8M | 5.4M | 9.0M | 8.5M | |
Total Liab | 22.1M | 29.8M | 151.9M | 158.5M | 257.0M | 269.8M | |
Total Current Assets | 137.0M | 419.8M | 74.6M | 68.0M | 124.2M | 124.3M | |
Accumulated Other Comprehensive Income | (80K) | (60K) | (175K) | (398K) | 40K | 42K | |
Short Term Debt | 4.6M | 2.3M | 377K | 2.3M | 2.2M | 2.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Boundless Bio, Common is a strong investment it is important to analyze Boundless Bio,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio,'s future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boundless Bio,. If investors know Boundless will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boundless Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.59) | Return On Assets (0.24) | Return On Equity (0.36) |
The market value of Boundless Bio, Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boundless Bio,'s market value can be influenced by many factors that don't directly affect Boundless Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boundless Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Boundless Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boundless Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.